Monoamine oxidase B (MAOB) is an enzyme involved in the metabolism of dopamine. It converts dopamine to its corresponding carboxylic acid via an aldehyde intermediate. MAOB regulates both the free intraneuronal concentration of dopamine and the releasable stores. MAOB inhibitors bind to and inhibit MAOB, preventing dopamine degradation. This results in greater stores of dopamine available for release. MAOB inhibitors are used in the treatment of depression. People with depression have higher levels of the brain protein MAOB than people without depression.
Click here: Learn about the role of MAO-B inhibitors in depression treatment
Related content
This slide deck summarizes the current knowledge surrounding the use of psychedelics for the treatment of depression. Specifically, our focus centers on serotonergic psychedelics, commonly referred to as classical psychedelics. These psychedelics primarily function as agonists or partial agonists at the serotonin 2A receptor (5-HT2A receptor).
The infographic shows a 27% increase in depression cases due to COVID-19, affecting 280 million people worldwide.
Dr. Jasmina Mallet highlights the latest research in psychiatric genetics, emphasizing the role of Polygenic Risk Scores (PRS) in psychiatry.